Cargando…
Severe hypocalcemia following a single injection of denosumab in a patient with renal impairment
Monitoring renal function and adjusting dosing for patients with impaired renal function are not required with denosumab (60 mg every 6 months). However, these patients have an increased risk for developing hypocalcemia. This case report describes a patient with renal impairment who developed severe...
Autor principal: | Talreja, Draupadi B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980727/ https://www.ncbi.nlm.nih.gov/pubmed/27536425 http://dx.doi.org/10.3109/21556660.2012.668504 |
Ejemplares similares
-
Severe Refractory Hypocalcemia Caused by Denosumab
por: Dadana, Sriharsha, et al.
Publicado: (2023) -
Severe Hypocalcemia due to Denosumab in Metastatic Prostate Cancer
por: Muqeet Adnan, Mohammed, et al.
Publicado: (2014) -
Severe, Symptomatic Hypocalcemia due to Denosumab Administration: Treatment and Clinical Course
por: Strickling, Jarred, et al.
Publicado: (2019) -
Denosumab Induced Severe Hypocalcemia in a Patient With Metastatic Prostate Cancer
por: Naher, Kamrun, et al.
Publicado: (2021) -
Importance of antiresorptive therapies for patients with bone metastases from solid tumors
por: Talreja, Draupadi B
Publicado: (2012)